论文部分内容阅读
１９９３年１１月—１９９４年１２月我院用盐酸米托蒽醌作Ⅲ期临床试验，观察治疗实体瘤５１例、白血病５例。其中淋巴瘤１４例，用ＣＮＯＰ方案治疗１０例，ＣＲ３例、ＰＲ４例、Ｓ２例、Ｐ１例；用ＮＶ方案治疗４例，ＣＲ２例、ＰＲ２例。肺癌２６例，用ＣＮＰ方案治疗１５例，ＣＲ１例、ＰＲ５例、Ｓ６例、Ｐ３例；用ＮＶ方案治疗１１例，ＣＲ１例、ＰＲ５例、Ｓ３例、Ｐ２例。胃癌４例、乳癌２例、鼻咽癌和膀胱癌各１例用ＮＶ方案治疗，ＰＲ３例、Ｓ３例、Ｐ１例（１例术后辅助化疗除外）。急性白血病５例用ＭＥ治疗，ＣＲ２例、Ｓ１例（两例死于颅内出血）；肺癌胸腔积液２例、肝癌腹腔积液１例用米托蒽醌腔内注射、ＣＲ１例、ＰＲ２例。本组化疗毒性反应与文献报告相似。
November 1993 - December 1994 in our hospital with mitoxantrone for phase Ⅲ clinical trial, observation and treatment of 51 cases of solid tumors, 5 cases of leukemia. Among them, 14 were lymphoma, 10 were treated with CNOP regimen, 3 were CR, 4 were PR, S2 were cases, and P1 was treated. There were 4 cases treated with NV regimen, CR2 cases and PR2 cases. There were 26 cases of lung cancer, 15 cases were treated with CNP regimen, CR1 cases, PR5 cases, S6 cases and P3 cases; 11 cases treated with NV regimen, CR1 cases, PR5 cases, S3 cases and P2 cases. 4 cases of gastric cancer, 2 cases of breast cancer, 1 case of nasopharyngeal carcinoma and 1 case of bladder cancer treated with NV regimen, PR3 cases, S3 cases and P1 cases (1 case except postoperative adjuvant chemotherapy). 5 cases of acute leukemia treated with ME, CR2 cases, S1 cases (two died of intracranial hemorrhage); 2 cases of lung cancer pleural effusion, liver cancer 1 case of mitoxantrone injection of mitoxantrone, CR1 cases, PR2 cases. This group of chemotherapy toxicity and literature reports similar.